Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase

SE Poplawski, JH Lai, Y Li, Z Jin, Y Liu… - Journal of medicinal …, 2013 - ACS Publications
SE Poplawski, JH Lai, Y Li, Z Jin, Y Liu, W Wu, Y Wu, Y Zhou, JL Sudmeier, DG Sanford…
Journal of medicinal chemistry, 2013ACS Publications
Fibroblast activation protein (FAP) is a serine protease selectively expressed on reactive
stromal fibroblasts of epithelial carcinomas. It is widely believed to play a role in tumor
invasion and metastasis and therefore to represent a potential new drug target for cancer.
Investigation into its biological function, however, has been hampered by the current
unavailability of selective inhibitors. The challenge has been in identifying inhibitors that are
selective for FAP over both the dipeptidyl peptidases (DPPs), with which it shares …
Fibroblast activation protein (FAP) is a serine protease selectively expressed on reactive stromal fibroblasts of epithelial carcinomas. It is widely believed to play a role in tumor invasion and metastasis and therefore to represent a potential new drug target for cancer. Investigation into its biological function, however, has been hampered by the current unavailability of selective inhibitors. The challenge has been in identifying inhibitors that are selective for FAP over both the dipeptidyl peptidases (DPPs), with which it shares exopeptidase specificity, and prolyl oligopeptidase (PREP), with which it shares endopeptidase specificity. Here, we report the first potent FAP inhibitor with selectivity over both the DPPs and PREP, N-(pyridine-4-carbonyl)-d-Ala-boroPro (ARI-3099, 6). We also report a similarly potent and selective PREP inhibitor, N-(pyridine-3-carbonyl)-Val-boroPro (ARI-3531, 22). Both are boronic acid based inhibitors, demonstrating that high selectivity can be achieved using this electrophile. The inhibitors are stable, easy to synthesize, and should prove to be useful in helping to elucidate the biological functions of these two unique and interesting enzymes, as well as their potential as drug targets.
ACS Publications